Free Trial
→ On January 2nd, the power gets cut (From Behind the Markets) (Ad)tc pixel Free EBS Stock Alerts

Emergent Biosolutions (EBS) Short Interest Ratio & Short Volume

Emergent Biosolutions logo
$8.16 +0.02 (+0.29%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Emergent Biosolutions Short Interest Overview

As of May 29, 2026, Emergent Biosolutions (EBS) had a short interest of 9.76 million shares sold short, representing 20.12% of the public float. This marks a 1.63% increase in short interest since the prior report. The short interest ratio (days to cover) is 11.5, meaning it would take 11.5 days of the average trading volume of 855,130 shares to cover all short positions.

Current Short Interest
9,760,594 shares
Previous Short Interest
9,604,080 shares
Change Vs. Previous Month
1.63%
Dollar Volume Sold Short
$88.98 million
Short Interest Ratio
11.5 Days to Cover
Last Record Date
May 29, 2026
Outstanding Shares
51,600,000 shares
Short Percent of Float
20.12%
Today's Trading Volume
119,986 shares
Average Trading Volume
855,130 shares
Today's Volume Vs. Average
14%
Short Selling Emergent Biosolutions?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Emergent Biosolutions and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

EBS Short Interest Over Time

EBS Days to Cover Over Time

EBS Percentage of Float Shorted Over Time

Emergent Biosolutions Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/29/20269,760,594 shares $88.98 million +1.6%20.1%11.5 $9.12
5/15/20269,604,080 shares $76.40 million -1.8%19.8%11.99 $7.96
4/30/20269,775,531 shares $81.19 million +1.4%20.1%18.42 $8.31
4/15/20269,643,974 shares $83.37 million -0.1%19.9%13.53 $8.65
3/31/20269,650,911 shares $80.06 million +8.7%19.9%11.29 $8.30
3/13/20268,875,813 shares $71.49 million -1.2%17.5%7.37 $8.06
2/27/20268,986,187 shares $73.57 million +1.3%17.7%7.67 $8.19
2/13/20268,870,355 shares $96.25 million +2.9%17.4%13.66 $10.85
1/30/20268,622,131 shares $97.73 million -2.2%17.0%9.83 $11.34
1/15/20268,818,514 shares $96.78 million -3.4%17.3%8.41 $10.98
12/31/20259,124,412 shares $112.69 million +1.2%17.9%12.15 $12.35
12/15/20259,020,934 shares $111.44 million +1.2%17.7%10.42 $12.35
11/28/20258,917,402 shares $99.61 million -3.7%17.5%10.86 $11.17
11/14/20259,260,505 shares $93.59 million +12.7%17.6%7.55 $10.11
10/31/20258,220,839 shares $102.22 million -6.9%15.6%5.17 $12.43
10/15/20258,830,000 shares $84.98 million -8.1%17.2%8 $9.62
9/30/20259,610,000 shares $84.66 million +8.5%18.8%8.4 $8.81
9/15/20258,860,000 shares $70.70 million +1.7%17.4%7 $7.98
8/31/20258,710,000 shares $72.16 million -11.3%17.1%6.8 $8.29
8/15/20259,820,000 shares $86.91 million -1.3%19.2%7.7 $8.85
7/31/20259,950,000 shares $58.44 million +9.8%19.5%7.2 $5.87
7/15/20259,060,000 shares $62.86 million -9.5%17.5%7.2 $6.94
6/30/202510,010,000 shares $63.86 million +25.3%19.3%7.9 $6.38
6/15/20257,990,000 shares $50.06 million +2.0%15.4%6.6 $6.27
5/31/20257,830,000 shares $49.68 million -1.0%15.1%6.4 $6.35
5/15/20257,910,000 shares $43.58 million +2.1%15.2%5.9 $5.51
4/30/20257,750,000 shares $41.31 million -14.1%14.9%6 $5.33
4/15/20259,020,000 shares $41.70 million +0.6%17.2%7.4 $4.62
3/31/20258,970,000 shares $43.53 million -2.1%17.1%7.4 $4.85
3/15/20259,160,000 shares $52.53 million +12.5%17.5%7.8 $5.74
2/28/20258,140,000 shares $60.68 million +14.8%15.4%7.1 $7.46
2/15/20257,090,000 shares $68.74 million +2.3%13.4%6.8 $9.70
1/31/20256,930,000 shares $78.63 million -1.6%13.1%5.8 $11.35
1/15/20257,040,000 shares $66.60 million -1.3%13.4%5.6 $9.46
12/31/20247,130,000 shares $68.16 million +2.7%13.5%5.6 $9.56
12/15/20246,940,000 shares $58.85 million +0.1%13.3%4.6 $8.48
11/30/20246,930,000 shares $70.13 million +1.8%13.3%4.3 $10.12
11/15/20246,810,000 shares $52.57 million -2.0%13.1%3.6 $7.72
10/31/20246,950,000 shares $62.90 million -10.8%13.4%2.9 $9.05
10/15/20247,790,000 shares $71.59 million -5.4%15.0%2.8 $9.19
On January 2nd, the power gets cut (Ad)

A federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day, a $45 billion Anthropic contract disappears with it. Musk can't wait years for permanent equipment. Analyst Dylan Jovine identified the one small company positioned to solve this problem nine months ago - and it's still priced like a boring industrial.tc pixel

See the one company Musk can't build Colossus without
9/30/20248,230,000 shares $68.64 million +84.1%15.9%2.7 $8.34
9/15/20244,470,000 shares $35.18 million +16.4%8.6%1.4 $7.87
8/31/20243,840,000 shares $31.91 million +11.0%7.6%1.2 $8.31
8/15/20243,460,000 shares $29.96 million -6.2%6.8%1.1 $8.66
7/31/20243,690,000 shares $46.90 million -19.1%7.3%1.3 $12.71
7/15/20244,560,000 shares $51.60 million -12.1%9.1%0.9 $11.32
6/30/20245,190,000 shares $35.40 million -18.0%10.3%1.1 $6.82
6/15/20246,330,000 shares $39.06 million +6.6%12.6%1.4 $6.17
5/31/20245,940,000 shares $33.86 million -1.7%11.8%1.3 $5.70
5/15/20246,040,000 shares $34.58 million -15.3%12.0%1.3 $5.73
4/30/20247,130,000 shares $13.40 million +21.1%14.1%1.2 $1.88
4/15/20245,890,000 shares $11.63 million +3.3%11.8%2 $1.98
3/31/20245,700,000 shares $14.42 million +16.1%11.4%1.9 $2.53
3/15/20244,910,000 shares $12.00 million -20.8%9.8%1.6 $2.45
2/29/20246,200,000 shares $19.96 million -46.3%12.5%2.1 $3.22
2/15/202411,540,000 shares $19.68 million +10.5%23.2%4.2 $1.71
1/31/202410,440,000 shares $17.43 million -11.7%21.0%7.8 $1.67
1/15/202411,820,000 shares $24.23 million +1.3%23.8%8.6 $2.05
12/31/202311,670,000 shares $28.01 million +3.0%23.5%8.4 $2.40
12/15/202311,330,000 shares $26.85 million +0.8%22.8%7.8 $2.37
11/30/202311,240,000 shares $24.05 million +4.3%22.6%6.6 $2.14
11/15/202310,780,000 shares $23.82 million -1.4%21.7%5.1 $2.21
10/31/202310,930,000 shares $22.84 million +21.9%22.0%4.7 $2.09
10/15/20238,970,000 shares $22.60 million +14.1%18.1%3.7 $2.52
9/30/20237,860,000 shares $26.72 million -16.9%15.8%3.3 $3.40
9/15/20239,460,000 shares $37.27 million +12.8%19.0%4 $3.94
8/31/20238,390,000 shares $39.35 million -9.3%16.8%3.9 $4.69
8/15/20239,250,000 shares $48.01 million +5.4%18.6%5.6 $5.19
7/31/20238,780,000 shares $60.36 million +5.0%18.1%5.8 $6.88
7/15/20238,360,000 shares $60.28 million +8.3%17.2%6.2 $7.21
6/30/20237,720,000 shares $56.66 million +9.8%15.9%5.3 $7.34
6/15/20237,030,000 shares $56.91 million +3.7%16.2%3.9 $8.10
5/31/20236,780,000 shares $57.83 million +6.8%15.5%3.9 $8.53
5/15/20236,350,000 shares $58.99 million -4.5%14.4%3.4 $9.29
4/30/20236,650,000 shares $58.72 million -7.5%15.1%3.7 $8.83
4/15/20237,190,000 shares $85.20 million -5.4%17.7%4.2 $11.85
3/31/20237,600,000 shares $78.74 million +22.4%18.7%4.6 $10.36
3/15/20236,210,000 shares $59.93 million +11.7%15.3%5.5 $9.65
2/28/20235,560,000 shares $68.83 million -1.1%13.7%5.1 $12.38
2/15/20235,620,000 shares $83.85 million No Change13.9%5.6 $14.92
1/31/20235,620,000 shares $74.13 million +4.9%13.9%5.7 $13.19
1/15/20235,360,000 shares $71.98 million -3.8%13.2%5.4 $13.43
12/30/20225,570,000 shares $65.78 million +63.3%13.7%5.8 $11.81
12/15/20223,410,000 shares $37.99 million +45.7%8.4%3.7 $11.14
11/30/20222,340,000 shares $28.78 million -9.0%5.7%2.9 $12.30
11/15/20222,570,000 shares $34.21 million +19.0%6.3%3.4 $13.31
10/31/20222,160,000 shares $45.06 million +6.4%5.3%3.4 $20.86
10/15/20222,030,000 shares $39.44 million -9.4%5.0%3.1 $19.43
9/30/20222,240,000 shares $47.02 million +9.3%5.5%3.4 $20.99
9/15/20222,050,000 shares $47.27 million +5.1%5.0%3.3 $23.06
Buy now or wait? (Ad)

SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much as 7,100% - buying SPCX stock isn't the best way to profit. A hidden SpaceX division, already live across the American South and unrelated to its launch business, could be worth 100 times more than SpaceX's core operations. Rob Spivey, Director of Research at Altimetry, breaks down exactly what it is and how to position for it.tc pixel

See the better way to potentially profit from the SpaceX IPO
8/31/20221,950,000 shares $46.84 million -34.8%4.8%3.1 $24.02
8/15/20222,990,000 shares $91.20 million -15.3%7.3%4.2 $30.50
7/31/20223,530,000 shares $122.28 million +2.6%8.6%4.7 $34.64
7/15/20223,440,000 shares $105.02 million +6.2%8.1%4.6 $30.53
6/30/20223,240,000 shares $100.57 million -3.6%7.6%4.4 $31.04
6/15/20223,360,000 shares $95.42 million -10.2%7.9%4.5 $28.40
5/31/20223,740,000 shares $123.27 million +12.0%9.1%4.9 $32.96
5/15/20223,340,000 shares $95.99 million -8.7%8.1%4.6 $28.74
4/30/20223,660,000 shares $118.51 million +13.3%8.9%6 $32.38
4/15/20223,230,000 shares $133.72 million +6.6%7.8%5.7 $41.40
3/31/20223,030,000 shares $124.41 million -8.5%7.3%5.2 $41.06
3/15/20223,310,000 shares $126.48 million -16.0%8.0%5.5 $38.21
2/28/20223,940,000 shares $163.04 million -5.1%9.3%5.9 $41.38
2/15/20224,150,000 shares $186.04 million +12.2%9.2%4.8 $44.83
1/31/20223,700,000 shares $173.16 million +5.4%8.2%4 $46.80
1/15/20223,510,000 shares $183.29 million +5.4%7.8%3.4 $52.22
12/31/20213,330,000 shares $144.76 million +21.5%7.4%3.4 $43.47
12/15/20212,740,000 shares $115.87 million +3.4%6.1%2.9 $42.29
11/30/20212,650,000 shares $116.92 million +63.6%5.5%3.2 $44.12
11/15/20211,620,000 shares $61.41 million -47.1%3.3%2.6 $37.91
10/29/20213,060,000 shares $145.87 million -4.7%6.3%5.8 $47.67
10/15/20213,210,000 shares $162.71 million -1.8%6.6%8.2 $50.69
9/30/20213,270,000 shares $163.73 million +2.2%6.8%7.9 $50.07
9/15/20213,200,000 shares $182.88 million -3.9%6.6%6.8 $57.15
8/31/20213,330,000 shares $210.06 million -5.9%6.9%6.4 $63.08
8/13/20213,540,000 shares $217.99 million -4.8%7.3%6.1 $61.58
7/30/20213,720,000 shares $245.15 million -0.5%7.7%5.9 $65.90
7/15/20213,740,000 shares $226.01 million +4.5%7.8%5.5 $60.43
6/30/20213,580,000 shares $225.50 million +20.5%7.4%4.5 $62.99

EBS Short Interest - Frequently Asked Questions

Short interest is the volume of Emergent Biosolutions shares that have been sold short but have not yet been covered or closed out. As of May 29th, investors have sold 9,760,594 shares of EBS short. 20.12% of Emergent Biosolutions' shares are currently sold short. Learn More on Emergent Biosolutions' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EBS shares currently have a short interest ratio of 11.5. Learn More on Emergent Biosolutions's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 20.12% of Emergent Biosolutions' floating shares are currently sold short.

Emergent Biosolutions saw a increase in short interest during the month of May. As of May 29th, there was short interest totaling 9,760,594 shares, an increase of 1.6% from the previous total of 9,604,080 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

20.12% of Emergent Biosolutions' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Emergent Biosolutions: Johnson & Johnson (0.97%), Innoviva, Inc. (8.10%), Novavax, Inc. (28.41%), Zenas BioPharma, Inc. (22.09%), OPKO Health, Inc. (8.70%), MannKind Corporation (10.08%), Lexicon Pharmaceuticals, Inc. (6.86%), Geron Corporation (11.38%), Rigel Pharmaceuticals, Inc. (23.75%), Ironwood Pharmaceuticals, Inc. (10.16%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($81.27 billion), Invesco QQQ ($49.06 billion), iShares Russell 2000 ETF ($23.61 billion), Western Digital Corporation ($16.93 billion), Sandisk Corporation ($15.61 billion), Salesforce Inc. ($11.65 billion), SPDR S&P Biotech ETF ($10.52 billion), Nebius Group N.V. ($10.24 billion), Lumentum Holdings Inc. ($8.74 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($8.21 billion). View all of the most shorted stocks.

Short selling EBS is an investing strategy that aims to generate trading profit from Emergent Biosolutions as its price is falling. EBS shares are trading up $0.40 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Emergent Biosolutions occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EBS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EBS, twice per month. The most recent reporting period available is May, 29 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like EBS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NYSE:EBS) was last updated on 6/18/2026 by MarketBeat.com Staff.
From Our Partners
Hopeless About Retirement? Hopeless and Helpless Aren’t the Same Thing
Your retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...
Golden Portfolio | Sponsoredtc pixel
Buy now or wait?
SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel